ARTV — Artiva Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1817241 ·
Last close
$6.80
Market Cap
$332.45M
52W High
$14.53
52W Low
$2.71
ADV30
454,121
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -26,890,000 | -25,005,000 | 368,633,000 | 301,454,000 | 21,131,000 |
| Mar 2026 | 0 | — | -24,430,000 | -23,516,000 | 105,955,000 | 20,955,000 | 18,108,000 |
| Dec 2025 | 0 | — | -21,932,000 | -20,772,000 | 130,940,000 | 26,701,000 | 20,970,000 |
| Sep 2025 | 0 | — | -22,897,000 | -21,528,000 | 148,862,000 | 25,508,000 | 19,638,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-75,232,000
Investing CF
$65,219,000
Financing CF
$282,999,000
CapEx
$-1,678,000
Dividends Paid
—
Buybacks
$-4,183,000
EPS Diluted TTM
$-3.33
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-379,070,000
Inventory
—
Receivables
$141,000
ST Investments
$47,940,000
EBIT TTM
$-96,149,000
Pretax Income TTM
$-90,821,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -89,810,000 | -83,865,000 | 130,940,000 | 20,970,000 | 109,970,000 | -76,751,000 |
| Dec 2024 | 251,000 | -67,282,000 | -58,179,000 | 209,581,000 | 22,940,000 | 186,641,000 | -55,032,000 |
| Dec 2023 | 33,492,000 | -30,671,000 | -32,766,000 | 105,114,000 | 267,129,000 | -162,015,000 | -47,430,000 |
| Dec 2022 | 4,931,000 | -59,829,000 | -60,976,000 | 133,054,000 | 273,750,000 | -140,696,000 | -50,829,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-87,070,000
OpCashFlow TTM
—
Assets (Latest)
$105,955,000
Forward EPS
$-2.61
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OCGN | Ocugen, Inc. | $331.45M | $0.98 | — |
| CABA | Cabaletta Bio, Inc. | $330.61M | $1.95 | — |
| SRZN | Surrozen, Inc./DE | $328.75M | $27.97 | — |
| AGEN | AGENUS INC | $339.45M | $7.54 | — |
| PROK | PROKIDNEY CORP. | $346.82M | $1.66 | — |
News headlines (Yahoo Finance, 1h cache)
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)
2026-10-01 11:30 · Yahoo
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
2026-09-23 11:30 · Yahoo
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
2026-09-17 12:00 · Yahoo
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
2026-09-08 11:30 · Yahoo
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
2026-09-02 12:30 · Yahoo
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-17 11:30 · Yahoo
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
2026-06-08 10:30 · Yahoo
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
2026-05-28 12:00 · Yahoo
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
2026-05-19 12:00 · Yahoo
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
2026-05-08 10:52 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.